The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Unitedhealth Group (NYSE:UNH), Merck & Co (NYSE:MRK), ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Elevance Health (NYSE:ELV), Gilead Sciences (NASDAQ:GILD), Boston Scientific Corp (NYSE:BSX).
The investment seeks to provide long-term growth of capital.
The fund invests at least 80% of its total assets in equity securities, primarily common stock, of companies in health sciences and related industries. The health sciences sector can include companies in health care equipment and supplies, health care providers and services, biotechnology, and pharmaceuticals. It will concentrate its investments (i.e., invest more than 25% of its assets) in health sciences or related industries, and may invest in companies located in non-U.S. countries.
The average market capitalization across the BlackRock Health Sciences Opps Instl MF is 187.75B. The market cap for tickers in the group ranges from 81.58B to 561.54B. LLY holds the highest valuation in this group at 561.54B. The lowest valued company is BSX at 81.58B.
The average weekly volume growth across all stocks in the BlackRock Health Sciences Opps Instl MF was 14%. For the same stocks of the MF, the average monthly volume growth was 8% and the average quarterly volume growth was 29%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 38
P/E Growth Rating: 44
Price Growth Rating: 45
SMR Rating: 59
Profit Risk Rating: 27
Seasonality Score: 0 (-100 ... +100)